Investors are correct to be giddy about Gilead Sciences’ (NASDAQ:GILD) second-quarter sales growth and its impact on the company’s financials, but second-quarter sales aren’t the only things that Gilead Sciences management offered insight into earlier this week.
The company also updated its outlook for its HIV program, its international sales, and its acquisition plans, too. Here are five quotes from Gilead Sciences’ second-quarter earnings conference call that investors ought to be aware of.
1. “Our newest antiviral agent path, which is under review as part of multiple products for the treatment of HIV, has a superior safety profile compared to TDF.
Help employers find you! Check out all the jobs and post your resume.
